Get the Stockscreener App
31.11
13.56%
-4.88
Pre-market:
28.21
-2.90
-9.32%
Monopar Therapeutics Inc stock is traded at $31.11, with a volume of 59,253.
It is down -13.56% in the last 24 hours and down -24.96% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$35.99
Open:
$35
24h Volume:
59,253
Relative Volume:
0.82
Market Cap:
$189.85M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-13.53
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-29.49%
1M Performance:
-24.96%
6M Performance:
+1,111%
1Y Performance:
+2,293%
1-Day Range:
$31.09
$35.27
1-Week Range:
$31.09
$45.60
52-Week Range:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
31.11 | 189.85M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
(MNPR) Trading Report - Stock Traders Daily
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World
Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat
What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat
Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire
Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - MSN
Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Piper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - MSN
(MNPR) Trading Advice - Stock Traders Daily
Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Brookline Capital Management Comments on MNPR Q1 Earnings - Defense World
Brookline Capital Management Predicts MNPR Q1 Earnings - MarketBeat
How To Know If Monopar Therapeutics Inc (NASDAQ:MNPR) Is Expensive At $24.46. - Marketing Sentinel
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Monopar Therapeutics Inc - GuruFocus.com
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - MSN
How the (MNPR) price action is used to our Advantage - Stock Traders Daily
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025 - Yahoo Finance
Monopar Therapeutics Inc. Enters Into Underwritten Registered Offering and Concurrent Private PlacementOn December 20, 2024, Monopar Therapeutics Inc. (NASDAQ: MNPR) finalized an Underwriting Agreement with Piper Sandler & Co. to conduct an Und - Defense World
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks Investment Research
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways (MNPR) - Seeking Alpha
(MNPR) Technical Data - Stock Traders Daily
Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants - The Manila Times
Monopar Therapeutics sets stock and warrant offering prices - Investing.com
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength - MSN
When the Price of (MNPR) Talks, People Listen - Stock Traders Daily
Monopar Therapeutics Achieves Milestone in Cancer Treatment - TipRanks
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):